Catalym Gmbh

This trial is testing whether adding an experimental drug called visugromab to standard first-line treatment helps people with newly diagnosed, advanced non-squamous lung cancer. About 107 participants will be randomly assigned to receive either the new combination or the standar…

This study is testing whether adding a new antibody drug called visugromab to standard treatments helps control advanced non-small cell lung cancer that has worsened after initial therapy. It will compare different combinations of visugromab, an immunotherapy drug (nivolumab), an…

This study is testing a new drug called visugromab to see if it can help people with advanced cancer who are losing weight and appetite, a condition called cachexia. Researchers want to know if the drug helps patients gain weight, feel hungrier, and be more active compared to a p…